King'S Score As A Novel Prognostic Model for Patients with Hepatitis B-Associated Hepatocellular Carcinoma

Qing Pang,Jian-Bin Bi,Xin-Sen Xu,Su-Shun Liu,Jing-Yao Zhang,Yan-Yan Zhou,Kai Qu,Chang Liu

DOI: https://doi.org/10.1097/meg.0000000000000452

2015-01-01

European Journal of Gastroenterology & Hepatology

Abstract:Background and objectives King's score (KS) has been developed to predict the presence of cirrhosis and hepatocellular carcinoma (HCC) in patients with chronic liver diseases. We aimed to investigate the prognostic significance of the KS in hepatitis B-associated HCC.Patients and methods We retrospectively analyzed 319 hepatitis B-associated HCC patients. Preoperative data were collected to calculate the KS (age x aspartate aminotransferase x international normalized ratio/platelet count). The primary outcomes were overall survival (OS) and disease-free survival (DFS), which was estimated using the Kaplan-Meier method. Then, we carried out a multivariate Cox analysis to assess the independent significance of the KS. Additional analyses were carried out after patients were stratified on the basis of cirrhosis status and therapy methods to investigate the significance of KS in different subgroups.Results During a median follow-up period of 44 months, 199 (62.4%) patients died and 144 (45.1%) experienced recurrence. The cut-off value for the KS was determined to be 33.31 with 56.8% sensitivity and 66.7% specificity. Compared with patients with low KS, the high group showed a higher probability of cirrhosis and worse Child-Pugh class (both P < 0.05). Multivariate analysis identified older age, tumor size 5 or more, palliative therapy, high Barcelona Clinic Liver Cancer stage, and high KS as significant factors for predicting poor OS and DFS. A combination of the KS and tumor size showed better discrimination ability for survival than Barcelona Clinic Liver Cancer stage.Conclusion The KS is an effective index for predicting OS and DFS in hepatitis B-associated HCC. Larger cohorts are needed to validate our finding. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.